{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T09:08:52Z","timestamp":1775034532684,"version":"3.50.1"},"reference-count":35,"publisher":"Public Library of Science (PLoS)","issue":"10","license":[{"start":{"date-parts":[[2019,10,24]],"date-time":"2019-10-24T00:00:00Z","timestamp":1571875200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0223944","type":"journal-article","created":{"date-parts":[[2019,10,24]],"date-time":"2019-10-24T13:28:28Z","timestamp":1571923708000},"page":"e0223944","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":5,"title":["Safety of intravitreal ziv-aflibercept in choroido-retinal vascular diseases: A randomised double-blind intervention study"],"prefix":"10.1371","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2573-9026","authenticated-orcid":true,"given":"Imoro Zeba","family":"Braimah","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8007-0073","authenticated-orcid":true,"given":"Ernest","family":"Kenu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kwesi N.","family":"Amissah-Arthur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen","family":"Akafo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kwaku Oppong","family":"Kwarteng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Winfried M.","family":"Amoaku","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2019,10,24]]},"reference":[{"issue":"4","key":"pone.0223944.ref001","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1093\/ije\/dyr050","article-title":"Non-communicable diseases in sub-Saharan Africa: what we know now","volume":"40","author":"S Dalal","year":"2011","journal-title":"Int J Epidem"},{"issue":"1","key":"pone.0223944.ref002","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1586\/17469899.3.1.43","article-title":"Trend of retinal diseases in developing countries","volume":"3","author":"H Nazimul","year":"2008","journal-title":"Exp Rev Ophthalmol"},{"issue":"5","key":"pone.0223944.ref003","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1136\/bjophthalmol-2011-300539","article-title":"Global estimates of visual impairment: 2010","volume":"96","author":"D Pascolini","year":"2012","journal-title":"Br J Ophthalmol"},{"issue":"4","key":"pone.0223944.ref004","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.ajo.2004.11.064","article-title":"Expression of VEGF and angiopoietins in subfoveal membranes from patients with age-related macular degeneration","volume":"139","author":"R Hera","year":"2005","journal-title":"Am J Ophthalmol"},{"issue":"10","key":"pone.0223944.ref005","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1016\/j.ophtha.2012.07.058","article-title":"Anti-vascular endothelial growth factor pharmacotherapy for diabetic macular edema: a report by the American Academy of Ophthalmology","volume":"119","author":"AC Ho","year":"2012","journal-title":"Ophthalmology"},{"issue":"4","key":"pone.0223944.ref006","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s11892-012-0289-0","article-title":"Novel targets against retinal angiogenesis in diabetic retinopathy","volume":"12","author":"S Wang","year":"2012","journal-title":"Curr diab rep"},{"issue":"21","key":"pone.0223944.ref007","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.2146\/ajhp130143","article-title":"Ziv-aflibercept: a novel angiogenesis inhibitor for the treatment of metastatic colorectal cancer","volume":"70","author":"C Chung","year":"2013","journal-title":"Am J Health Syst Pharm"},{"key":"pone.0223944.ref008","unstructured":"Shah GK ST. 2017 Global Trends in Retina Survey. Chicago, IL.; 2017."},{"issue":"10","key":"pone.0223944.ref009","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1038\/eye.2015.159","article-title":"Defining response to anti-VEGF therapies in neovascular AMD","volume":"29","author":"WM Amoaku","year":"2015","journal-title":"Eye (Lond)"},{"issue":"9","key":"pone.0223944.ref010","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1097\/IAE.0000000000001000","article-title":"Intravitreal injections of ziv-aflibercept for diabetic macular edema: A Pilot Study","volume":"36","author":"GC Andrade","year":"2016","journal-title":"Retina (Philadelphia, Pa)"},{"issue":"1","key":"pone.0223944.ref011","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1136\/bjophthalmol-2017-310318","article-title":"One-year outcome of intravitreal ziv-aflibercept therapy for non-responsive neovascular age-related macular degeneration","volume":"102","author":"IZ Braimah","year":"2018","journal-title":"Br J Ophthalmol"},{"issue":"6","key":"pone.0223944.ref012","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1097\/IAE.0000000000000913","article-title":"Short-term safety profile of intravitreal ziv-aflibercept","volume":"36","author":"J Chhablani","year":"2016","journal-title":"Retina (Philadelphia, Pa)"},{"issue":"4","key":"pone.0223944.ref013","doi-asserted-by":"crossref","first-page":"245","DOI":"10.3928\/23258160-20180329-06","article-title":"Intravitreal Ziv-Aflibercept for Diabetic Macular Edema: 48-Week Outcomes","volume":"49","author":"GC de Andrade","year":"2018","journal-title":"Ophthalmic surg, Lasers & Imaging Retina"},{"key":"pone.0223944.ref014","article-title":"Intravitreal ziv-aflibercept for neovascular age-related macular degeneration: 52-Week Results","author":"JR de Oliveira Dias","year":"2017","journal-title":"Retina (Philadelphia, Pa)"},{"issue":"8","key":"pone.0223944.ref015","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1136\/bjophthalmol-2014-306319","article-title":"Ziv-aflibercept in macular disease","volume":"99","author":"AM Mansour","year":"2015","journal-title":"Br J Ophthalmol"},{"issue":"10","key":"pone.0223944.ref016","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1136\/bjophthalmol-2017-311591","article-title":"Two-year outcomes of intravitreal ziv-aflibercept","volume":"102","author":"AM Mansour","year":"2018","journal-title":"Br J Ophthalmol"},{"issue":"12","key":"pone.0223944.ref017","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1136\/bjophthalmol-2015-308319","article-title":"Three-month outcome of ziv-aflibercept for exudative age-related macular degeneration","volume":"100","author":"AM Mansour","year":"2016","journal-title":"Br J Ophthalmol"},{"key":"pone.0223944.ref018","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.2147\/OPTH.S116343","article-title":"Intravitreal ziv-aflibercept for macular edema following retinal vein occlusion","volume":"10","author":"R Paulose","year":"2016","journal-title":"Clin Ophthalmol"},{"issue":"10","key":"pone.0223944.ref019","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1097\/IAE.0000000000001440","article-title":"Short-term safety of 2mg intravitreal ziv-aflibercept","volume":"37","author":"J Chhablani","year":"2017","journal-title":"Retina (Philadelphia, Pa)"},{"key":"pone.0223944.ref020","article-title":"Safety of 5914 intravitreal ziv-aflibercept injections","author":"SR Singh","year":"2018","journal-title":"Br J Ophthalmol"},{"issue":"3","key":"pone.0223944.ref021","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.ajo.2005.03.057","article-title":"Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop","volume":"140","author":"DA Jabs","year":"2005","journal-title":"Am J Ophthalmol"},{"issue":"8","key":"pone.0223944.ref022","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1097\/OPX.0b013e31812f7690","article-title":"The Eye Sensation Scale: an ophthalmic pain severity measure","volume":"84","author":"LE Caudle","year":"2007","journal-title":"Optom Vis Sci"},{"issue":"2","key":"pone.0223944.ref023","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s40123-013-0015-2","article-title":"Aflibercept for the treatment of age-related macular degeneration","volume":"2","author":"G Trichonas","year":"2013","journal-title":"Ophthalmol Ther"},{"issue":"9","key":"pone.0223944.ref024","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1097\/IAE.0000000000001000","article-title":"Intravitreal injections of ziv-aflibercept for diabetic macular edema: A Pilot Study","volume":"36","author":"GC Andrade","year":"2016","journal-title":"Retina"},{"issue":"7","key":"pone.0223944.ref025","doi-asserted-by":"crossref","first-page":"e669","DOI":"10.1111\/aos.13111","article-title":"Three-month outcomes of ziv-aflibercept in the treatment of diabetic macular oedema","volume":"94","author":"M Ashraf","year":"2016","journal-title":"Acta Ophthalmol"},{"issue":"5","key":"pone.0223944.ref026","doi-asserted-by":"crossref","first-page":"469","DOI":"10.4103\/0301-4738.159909","article-title":"Intravitreal ziv-aflibercept for recurrent macular edema secondary to central retinal venous occlusion","volume":"63","author":"J Chhablani","year":"2015","journal-title":"Indian J Ophthalmol"},{"issue":"1","key":"pone.0223944.ref027","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3928\/23258160-20150101-17","article-title":"Intravitreal injection of ziv-aflibercept in patient with refractory age-related macular degeneration","volume":"46","author":"JR de Oliveira Dias","year":"2015","journal-title":"Ophthalmic Surg, Lasers & Imaging Retina"},{"issue":"12","key":"pone.0223944.ref028","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1136\/bjophthalmol-2015-308319","article-title":"Three-month outcome of ziv-aflibercept for exudative age-related macular degeneration","volume":"100","author":"AM Mansour","year":"2016","journal-title":"Br J Ophthalmol"},{"issue":"2","key":"pone.0223944.ref029","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1136\/bjophthalmol-2016-308679","article-title":"Three-month outcome of intravitreal ziv-aflibercept in eyes with diabetic macular oedema","volume":"101","author":"AM Mansour","year":"2017","journal-title":"Br J Ophthalmol"},{"issue":"3","key":"pone.0223944.ref030","article-title":"Three-Month Outcome of Ziv-Aflibercept for Diabetic Macular Edema","volume":"4","author":"A Marashi","year":"2016","journal-title":"Adv Ophthalmol Vis Syst"},{"issue":"Suppl 1","key":"pone.0223944.ref031","doi-asserted-by":"crossref","first-page":"i11","DOI":"10.1136\/bjophthalmol-2014-305302","article-title":"Safety profiles of anti-VEGF drugs: bevacizumab, ranibizumab, aflibercept and ziv-aflibercept on human retinal pigment epithelium cells in culture","volume":"98","author":"D Malik","year":"2014","journal-title":"Br J Ophthalmol"},{"issue":"6","key":"pone.0223944.ref032","doi-asserted-by":"crossref","first-page":"577","DOI":"10.3928\/23258160-20141118-15","article-title":"Preclinical investigations of intravitreal ziv-aflibercept","volume":"45","author":"JR de Oliveira Dias","year":"2014","journal-title":"Ophthalmic Surg, Lasers & Imaging Retina"},{"issue":"9","key":"pone.0223944.ref033","first-page":"1508.e1","article-title":"Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age-related macular degeneration","volume":"113","author":"U Chakravarthy","year":"2006","journal-title":"Ophthalmology"},{"issue":"2","key":"pone.0223944.ref034","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.oret.2016.08.007","article-title":"Two Doses of Intravitreal Ziv-Aflibercept versus Bevacizumab in Treatment of Diabetic Macular Edema: A Three-Armed, Double-Blind Randomized Trial","volume":"1","author":"A Baghi","journal-title":"Ophthalmology Retina"},{"issue":"5","key":"pone.0223944.ref035","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.oret.2017.09.010","article-title":"One-Year Results of a Trial Comparing 2 Doses of Intravitreal Ziv-aflibercept versus Bevacizumab for Treatment of Diabetic Macular Edema","volume":"2","author":"MH Jabbarpoor Bonyadi","year":"2018","journal-title":"Ophthalmology Retina"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0223944","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,8]],"date-time":"2020-05-08T16:50:22Z","timestamp":1588956622000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0223944"}},"subtitle":[],"editor":[{"given":"Gianni","family":"Virgili","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2019,10,24]]},"references-count":35,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2019,10,24]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0223944","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.17504\/protocols.io.2dwga7e","asserted-by":"object"}]},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,24]]}}}